Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard-Jules Laforgue

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
International Journal of Environmental Research and Public Health|November 27, 2021
Regulatory Framework Implementation for the Prescription of Zolpidem in France, What Impact in the Older People?Alexandra Jobert, Marion Istvan, Edouard-Jules Laforgue, et al.
Journal of Addiction Medicine|September 2, 2024
Cannabinoid Hyperemesis Syndrome Presumed Secondary to CBD Use: A Case ReportEmilie Lefebvre, Luc Simons, Mélanie Duval, et al.
Addiction Science & Clinical Practice|October 16, 2024
Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA studyMélanie Pinhal, Benoit Schreck, Juliette Leboucher, et al.
International Journal of Environmental Research and Public Health|July 28, 2022
Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among UsersEdouard-Jules Laforgue, Morgane Rousselet, Antoine Claudon, et al.
European Addiction Research|December 2, 2024
ESCAPE Study: Cannabidiol Use in Patients Treated for Substance Use Disorders, Prevalence of Use, and Characteristics of UsersMélanie Duval, Marion Istvan, Morgane Rousselet, et al.
International Journal of Geriatric Psychiatry|April 14, 2020
Do older people know why they take benzodiazepines? A national French cross-sectional survey of long-term consumersEdouard-Jules Laforgue, Alexandra Jobert, Morgane Rousselet, et al.
Therapie|August 21, 2025
Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance databaseLouis Asselin, Edouard-Jules Laforgue, Mélanie Duval, et al.
Journal of Affective Disorders|January 20, 2024
Drug-induced depressive symptoms: An update through the WHO pharmacovigilance databaseJulien Li, Yoann Zelmat, Wilhelm Storck, et al.
Acta Psychologica|June 27, 2026
Subtyping binge-watchers based on viewing patterns and motives: A latent class analysisVincent Bresdin, Marianne Balem, Gaëlle Challet-Bouju, et al.
Journal of Clinical Medicine|April 23, 2022
Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription BehaviorEdouard-Jules Laforgue, Marion Istvan, Benoit Schreck, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
International Journal of Environmental Research and Public Health|November 27, 2021
Regulatory Framework Implementation for the Prescription of Zolpidem in France, What Impact in the Older People?Alexandra Jobert, Marion Istvan, Edouard-Jules Laforgue, et al.
Journal of Addiction Medicine|September 2, 2024
Cannabinoid Hyperemesis Syndrome Presumed Secondary to CBD Use: A Case ReportEmilie Lefebvre, Luc Simons, Mélanie Duval, et al.
Addiction Science & Clinical Practice|October 16, 2024
Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA studyMélanie Pinhal, Benoit Schreck, Juliette Leboucher, et al.
International Journal of Environmental Research and Public Health|July 28, 2022
Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among UsersEdouard-Jules Laforgue, Morgane Rousselet, Antoine Claudon, et al.
European Addiction Research|December 2, 2024
ESCAPE Study: Cannabidiol Use in Patients Treated for Substance Use Disorders, Prevalence of Use, and Characteristics of UsersMélanie Duval, Marion Istvan, Morgane Rousselet, et al.
International Journal of Geriatric Psychiatry|April 14, 2020
Do older people know why they take benzodiazepines? A national French cross-sectional survey of long-term consumersEdouard-Jules Laforgue, Alexandra Jobert, Morgane Rousselet, et al.
Therapie|August 21, 2025
Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance databaseLouis Asselin, Edouard-Jules Laforgue, Mélanie Duval, et al.
Journal of Affective Disorders|January 20, 2024
Drug-induced depressive symptoms: An update through the WHO pharmacovigilance databaseJulien Li, Yoann Zelmat, Wilhelm Storck, et al.
Acta Psychologica|June 27, 2026
Subtyping binge-watchers based on viewing patterns and motives: A latent class analysisVincent Bresdin, Marianne Balem, Gaëlle Challet-Bouju, et al.
Journal of Clinical Medicine|April 23, 2022
Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription BehaviorEdouard-Jules Laforgue, Marion Istvan, Benoit Schreck, et al.
Pageof 4